Description:
Summary
RNA signature that can differentiate between colorectal cancer patients having a partial or no response to radiation therapy. This signature can also be used as a biomarker to predict which patients will respond to standard-of-care radiation therapy, enabling the clinical management of the non-responding patient to encompass alternative neoadjuvant therapy.
Technology Overview
The standard of care for patients with a diagnosis of colorectal cancer is radiation therapy to reduce tumor size, followed by surgery. However, colorectal cancer patients do not respond equally to radiation therapy. Researchers at OHSU have identified an RNA signature comprised of a microRNA and 4 target genes (mRNAs) that can differentiate between colorectal cancer patients having a partial or no response to radiation therapy. In particular, this signature can be used as a biomarker to predict which patients will respond to standard of care radiation therapy, enabling the clinical management of the non-responding patient to encompass alternative neoadjuvant therapy.
Technology at a glance:
- RNA signature is differentially expressed in colorectal cancer patients relative to radiation therapy response.
- RNA signature can be used as a biomarker to identify colorectal cancer patients that will or will not benefit from neoadjuvant radiation therapy.
Publications
Kelley KA, et al., "Understanding and Resetting Radiation Sensitivity in Rectal Cancer." Ann Surg. 266(2017):610-616.Link
Ruhl, R. et al., "microRNA-451a regulates colorectal cancer proliferation in response to radiation." BMC Cancer 18(2018): 4370-1. Link
Licensing Opportunity
This technology is available for exclusive licensing.